LGLaura Gómez-Dabó

Laura Gómez-Dabó

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Gómez-Dabó has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross‐sectional study

    by Laura Gómez‐Dabó, Rut Mas‐De‐Les‐Valls, Ane Murillo, Víctor J. Gallardo, Marta Torres‐Ferrús, Alicia Alpuente, Teresa Mateu, Eulàlia Giné‐Ciprés, Edoardo Caronna, Patricia Pozo‐Rosich

    Background and Objectives: Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers. Methods: A cross‐sectional study was conducted including females aged 18–60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen‐only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross‐checked with medical records and phone interviews. Age‐ and size‐matched analyses compared HT users and nonusers, and comparisons among HT types were also performed. Results: A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p ‐values > 0.05). Among females in the RS and regular menstrual cycles ( n = 78), menstrually‐related migraine was highly prevalent (67/78; 86%). In the RS group comparisons ( n = 109), no differences according to HT use in migraine characteristics or menstruation‐related symptoms were observed (all adjusted p ‐values > 0.05). Similarly, among females in the menopause transition ( n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p ‐values > 0.05). Conclusions: In this real‐world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually‐related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.

  • Long‐term mortality after status epilepticus: A 5‐year analysis study

    by Manuel Alanís‐Bernal, Daniel Campos‐Fernández, Laura Abraira, Laura Gómez‐Dabó, Marc Rodrigo‐Gisbert, Manuel Quintana, Sofía Lallana, Elena Fonseca, Samuel López‐Maza, Manuel Toledo, et al.

    Objective: To describe 5‐year mortality after status epilepticus (SE) and identify factors associated with long‐term survival. We also validated the prognostic performance of the Age, Consciousness, Duration (ACD) score and evaluated long‐term survival across etiological categories defined by the Lattanzi classification of acute symptomatic SE. Methods: Retrospective cohort analysis of a prospectively maintained database of consecutive patients ≥16 years of age with confirmed SE admitted to a tertiary epilepsy center (2011–2022). We excluded unclear diagnoses, hypoxic–anoxic etiologies, and incomplete follow‐up. We recorded clinical variables and prognostic scores modified Status Epilepticus Severity Score (mSTESS), Epidemiology‐based Mortality Status Epilepticus (EMSE), and Age, Consciousness, Duration (ACD). Mortality was assessed at discharge and annually up to 5 years. Results: We included 786 patients (mean age 63.4 years, 43.5% female). Five‐year mortality was 50.3%, with 44.0% of deaths occurring within the first 2 years. Neurological causes accounted for 60.8% of deaths, and direct seizure‐related causes represented 74.6% of neurological deaths. Independent predictors of higher long‐term mortality were older age, higher premorbid mRS, absence of prior seizure history, comorbidity burden, systemic complications, and impaired consciousness during SE; convulsive and focal motor SE were associated with lower mortality risk. mSTESS and EMSE were associated with long‐term mortality. In patients with less damaging etiologies, ACD predicted 5‐year mortality (hazard ratio [HR] 1.163, 95% confidence interval [CI] 1.063–1.273; area under the curve [AUC] 0.717); ACD ≥10 corresponded to >50% 2‐year mortality. Five‐year mortality was 61.3% (acute‐primary Central Nervous System (CNS) and 58.3% (acute‐secondary CNS). Significance: SE carries substantial long‐term mortality, particularly within the first 2 years. Neurological and seizure‐related causes were the most frequent. The Lattanzi classification and the ACD score retained long‐term prognostic value.

  • Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves-Castellanos, Leonardo Portocarrero, Gloria Vaghi, Joana Rodríguez-Montolio, Alex Jaimes, Albert Muñoz-Vendrell, et al.


  • Open Access

    Optimizing Chronic Migraine Care: The Impact of Advanced Practice Nurse Involvement in OnabotulinumtoxinA Administration

    by Eulalia Gine-Cipres, Marta Torres-Ferrus, Víctor J Gallardo, Alicia Alpuente Ruiz, Edoardo Caronna, Laura Gomez-Dabo, Patricia Pozo-Rosich

    Background: Chronic migraine is a disabling and prevalent neurological disease that significantly impacts patients' quality of life. OnabotulinumtoxinA (OnabotA) is a safe and effective chronic migraine preventive treatment. The objective was to evaluate adherence to the recommended time interval between consecutive OnabotA injections according to the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) protocol, and to analyze changes in the interval adherence before and after the introduction of an Advanced Practice Nurse (APN) in a specialized Headache Unit of a tertiary hospital. Methods: This was a retrospective study performed in a Spanish specialized Headache Clinic. Patients diagnosed with chronic migraine and treated with OnabotA following the PREEMPT protocol were included, before and after the introduction of APNs. Treatment was considered interval-compliant if the injection interval ranged from 75 to 105 days. The data collected included three 18-month periods. Statistical analyses examined differences across periods using R-Studio. Results: A total of 2991 participants were included, of whom 83.8% (2507/2991) were women, with a median age [interquartile range (IQR)] of 48.0 [40.0–57.0] years old. A statistically significant association between the introduction of the APN and improved adherence to the PREEMPT protocol was observed over time (Z = –19.60, p < 0.001). Adherence rates increased from 52.1% in P1 to 76.1% in both P2 and P3. The median time between visits decreased from 105 days in P1 to 96 days in P2, with a slight increase to 98 days in P3. Conclusion: The involvement of advanced practice nurses in OnabotA administration decreased the time interval between infiltrations and improved adherence to the PREEMPT protocol. These findings highlight the APN's role in optimizing patient care.

  • Top Cited Papers

    Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves-Castellanos, Leonardo Portocarrero-Sánchez, Gloria Vaghi, Joana Rodríguez-Montolio, Alex Jaimes, Albert Muñoz-Vendrell, et al.

    The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.


  • Open Access

    The interplay between migraine, endometriosis and polycystic ovarian syndrome: A systematic review

    by Laura Gómez-Dabó, Teresa Jordà-Baleri, Helena Losa-Puig, Edoardo Caronna, Patricia Pozo-Rosich

    Background: Migraine and gynecological conditions, such as endometriosis (EDM) and polycystic ovarian syndrome (PCOS), are highly prevalent among females and appear to influence each other, with a potential shared pathophysiological mechanism. Therefore, this study aims to provide a comprehensive summary of the current evidence regarding the relationship between migraine and EDM/PCOS from a clinical perspective. Methods: A systematic review was conducted using four databases (MEDLINE(Pubmed), EMBASE (Elsevier), Web of Science and Cochrane Library) along with searches in the grey literature. The protocol was registered prospectively on the PROSPERO platform (CRD42024628010). The primary search was performed on 4 December 2024. Eligible studies included observational studies that compared two or more groups of females with migraine, EDM and/or PCOS diagnosis. The modified Newcastle-Ottawa Scale was used to assess the quality of the included studies. Data extraction was performed and results systematically analyzed. Results: From an initial 408 identified studies, a final selection of 15 was analyzed (14 focused on EDM and 1 on PCOS) with a total of 289,519 individuals included. All selected studies achieved a score of 6 or higher on the mNOS. When comparing females with and without EDM, the prevalence of migraine reached up to 44.7%, with females affected with EDM having up to a five-fold increased risk of developing migraine (adjusted odds ratio = 5.35, 95% confidence interval = 2.11–16.4). When comparing females with and without migraine, a higher prevalence and risk of EDM was observed, with rates reaching 53.4% and an adjusted odds ratio up to 10.5 (95% confidence interval = 2.2–51.4). Mixed findings were found regarding the influence of EDM on migraine characteristics, as well as the impact of migraine in EDM-related symptoms and disease severity. Females with migraine and EDM exhibited higher scores in disability assessment tools (Headache Impact Test-6, 30-item Endometriosis Health Profile), suggesting a greater disease burden. Due to the limited data, no conclusions could be drawn regarding a link between PCOS and migraine. Conclusions: Although further high-quality research is required to better understand the underlying mechanisms linking migraine, EDM and PCOS, the current evidence supports a significant association between migraine and endometriosis. Trial Registration: PROSPERO Registration ID: CRD42024628010.


  • Open Access

    Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor

    by Laura Gómez‐Dabó, Víctor J. Gallardo, Daniel Campos‐Fernández, Marc Rodrigo‐Gisbert, Maider Iza‐Achutegui, Anna Sánchez, Fuat Arikan, Estevo Santamarina, Edoardo Caronna, Patricia Pozo‐Rosich

    Objectives/Background: Persistent headache (PH) after an aneurysmal subarachnoid hemorrhage (aSAH) and the influence of migraine history (MH) on its evolution and prognosis is poorly understood. Our study aims are to (1) determine the prevalence, characteristics, and prognostic factors of PH after aSAH; and (2) study the impact of personal MH on PH and aSAH prognosis. Methods: This retrospective cohort study included all adults with confirmed aSAH from January 2019 to September 2021 at a tertiary hospital. Data collected included demographics, comorbidities (including personal MH before aSAH), complementary tests, and aneurysm characteristics. The following clinical, radiological, and functional assessment scales were used: Glasgow Coma Scale (GCS), World Federation of Neurosurgical Societies (WFNS) grading scale, Hunt and Hess grading system, modified Fisher scale, VASOGRADE score, APACHE II score, and the modified Rankin Scale (mRS). PH was defined following the definition of persistent headache attributed to past nontraumatic subarachnoid hemorrhage (6.2.4.2) in the International Classification of Headache Disorders, 3rd edition. PH characteristics were assessed via phone interviews. Descriptive analyses were conducted, along with group comparisons and regression models exploring associations between MH, PH, functional outcomes, and survival. Results: A total of 130 individuals with aSAH were included with a median age of 59.0 (interquartile range, 51.0–70.0) years and 62.3% (81 of 130) were female. For PH assessment, a total of 36.9% (48 of 130) individuals were excluded due to death, and 19.5% (16 of 82) due to lack of phone availability, resulting in a final sample of 66 individuals. PH had a prevalence of 47.0% (31 of 66) at a mean‐time follow up of 3.12 ± 0.83 years. PH primarily manifested with moderate intensity (median visual analogue scale, 7), bilateral localization (51.6%; 16 of 31), and oppressive quality (77.4%; 24 of 31), with a minority of individuals experiencing nausea/vomiting (29.0%; 9 of 31) or photo/phonophobia (41.9%; 13 of 31). Up to 61.3% (19 of 31), referred moderate–severe interference of PH on daily activities. A personal MH was the only risk factor for developing PH (adjusted odds ratios [aOR], 3.9; 95% confidence interval [CI], 1.24–13.2; p = 0.022), and was present in up to 48.5% individuals (32 of 66). MH was associated with decreased aSAH clinical severity risk in both Hunt and Hess (adjusted p [adj. p ] = 0.038) and WFNS (adj. p = 0.038) scales, better function outcomes (mRS) at discharge and at 3 months of follow‐up (adj. p = 0.002 and adj. p = 0.003), and was independently associated with aSAH survival (aOR, 3.3; 95% CI, 1.14–11.06; p = 0.037). Conclusion: Persistent headache affected up to 47% individuals in the long term following aSAH and significantly impacted their quality of life. A history of migraine appeared to be more common among individuals with aSAH and was associated with a three‐fold increase in survival (aOR, 3.3); however, it also served as a risk factor for developing PH.

  • Open Access

    Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days

    by Rut Mas-De-Les-Valls, Laura Gómez-Dabó, Edoardo Caronna, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich

    Background: Data on the effectiveness of preventive treatments on menstrually-related migraine (MRM) is scarce. Our objective was to analyze the efficacy of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) and onabotulinumtoxinA (BTX-A) in the reduction of perimenstrual headache days (PHD) and perimenstrual migraine days (PMD) compared to non-perimenstrual headache days (non-PHD) and non-perimenstrual migraine days (non-PMD) per month in women with MRM. Methods: A retrospective study was conducted including females with menstruation and headache records, treated with either anti-CGRP mAbs or BTX-A. Patients completed e-Diary one month before and three months after preventive treatment. We collected clinical data and analyzed PHD/PMD and non-PHD/non-PMD before and after treatment. Additional analyses included PHD/PMD and non-PHD/non-PMD comparisons grouped by aura, episodic/chronic migraine, treatment and contraceptive intake. Results: We analyzed data from 113 females with a median (range) age of 39.0 (33.0–45.0) years. When combining patients treated with anti-CGRP mAbs or BTX-A, a median (range) of 2.0 (2.0–3.0) PHD/month (corresponding to 13.6% baseline monthly headache days (MHD)) and 13.0 (9.0–17.0) non-PHD/month pre-treatment was observed. From these, 2.0 (1.0–3.0) were PMD/month, and 7.0 (4.0–11.0) were non-PMD/month. After treatment, the median PHD/month was 2.0 (1.0–3.0) (corresponding to 16.67% of MHD) ( p = 0.085), and 8.0 (5.0–13.0) were non-PHD/month ( p < 0.001); from these, 1.0 (0.0–3.0) were PMD/month (proportion difference, p = 0.035) and 4.0 (2.0–7.0) were non-PMD (proportion difference, p < 0.001). When analyzing grouped by treatment, only patients treated with anti-CGRP experienced a reduction in PMD. No statistically significant differences in clinical factors (aura, migraine diagnosis, contraceptive intake) between PHD/non-PHD or PMD/non-PMD, either pre- or post-treatment. A higher probability risk of headache and migraine during the perimenstrual window was observed independently of the treatment received (odds ratio = 1.637, 95% confidence interval = 1.356–1.984, p < 0.001). Conclusions: Three-month treatment with anti-CGRP mAbs or BTX-A effectively reduced non-PHD and non-PMD but had limited effect on PHD/PMD because headache probability risk was higher during the perimenstrual window after treatment.


  • Open Access

    Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine

    by Laura Gómez-Dabó, Edoardo Caronna, Rut Mas-De-Les-Valls, Víctor J. Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich

    Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days—MHD; monthly migraine days—MMD; acute medication days/month—AMDM) and side effect data were collected. A ≥ 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14.75–17], 70% (14/20) females). The median basal frequencies were 28.8 [20–28] MHD, 18 [10–28] MMD and 10 [7.5–21.2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of −20 days/month (p = 0.001). At 12 months (n = 14), eight patients (57.1%) were responders, with a median reduction in MHD of −17.5 days/month (p = 0.002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives.